Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical...
32 insider purchases on record · latest filing 2026-08-21.
Insiders have also filed 403 sale transactions at PRTA.